Aberrant p53 function, due to 17p deletion (del(17p)) and/or TP53 mutation, is associated with poor prognosis in chronic lymphocytic leukemia (CLL) patients [3–5]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.